Cefepime

## Report on Cefepime Urticaria Labeling Amendment **1. Executive Summary:** This report analyzes a directive issued by the Central Drugs Standard Control Organization (CDSCO), Government of India, mandating the inclusion of Urticaria (hives) as an adverse drug reaction in the prescribing information leaflet (PIL), package insert, and promotional literature of the antibiotic Cefepime. This amendment is based on recommendations from the Pharmacovigilance Programme of India (PvPI) and the Subject Expert Committee (SEC) following the review of adverse drug reaction (ADR) reports. The key finding is that manufacturers of Cefepime formulations are now required to update their labeling to reflect this new adverse reaction. **2. Introduction:** This report aims to provide a comprehensive overview of the CDSCO directive regarding the labeling of Cefepime formulations. The analysis is solely based on the provided policy text (F. No. 120118DC Pt337). This report informs the affected industry about the recent changes mandated by the regulatory body. **3. Policy Overview:** * This document represents an **amendment** to existing regulations concerning the labeling of Cefepime. * **Core Objective:** The core objective is to enhance patient safety by ensuring that Urticaria is listed as a known adverse drug reaction (ADR) associated with Cefepime, and that it is included in all prescribing information. This is to ensure that patients and healthcare providers are aware of this potential risk. **4. Background and Rationale:** This amendment arises from the detection of a safety signal related to Cefepime and Urticaria, identified through the Pharmacovigilance Programme of India (PvPI). The PvPI, analyzing ADR reports (Individual Case Study Reports - ICSRs), recommended the inclusion of Urticaria in the Cefepime prescribing information. This indicates that there was likely under-reporting or a lack of awareness regarding Urticaria as a potential side effect of Cefepime, necessitating a change to current labeling practices. **5. Key Provisions / Changes:** This document focuses *specifically* on the following changes introduced regarding the labeling of Cefepime: * **Original Policy Change:** The policy being changed is the existing labeling requirements for Cefepime, which apparently did not previously include Urticaria as a listed adverse reaction. * **New Rule/Provision:** The *new* rule is that manufacturers of Cefepime formulations are *required* to "mention Urticaria as an adverse drug reaction in the label/Package insert/Promotional Literature of the drug." This includes the prescribing information leaflet (PIL). * **Difference/Effect:** The effect of this change is that all Cefepime products distributed in India must now clearly state that Urticaria is a potential side effect. This will increase awareness among healthcare professionals and patients, potentially leading to earlier recognition and management of this ADR. **6. Target Audience and Stakeholders:** The primary target audience is: * **Manufacturers of Cefepime formulations** operating under the jurisdiction of State/UT Drugs Controllers. They are directly responsible for implementing the labeling changes. Other stakeholders include: * **State/UT Drugs Controllers:** They are tasked with directing manufacturers and ensuring compliance. * **Healthcare Professionals (Doctors, Pharmacists):** They need to be aware of this change to properly inform patients. * **Patients:** Ultimately, they are the intended beneficiaries of the increased awareness regarding potential side effects. **7. Implementation Aspects (Inferred):** * **Responsible Agency/Bodies:** * CDSCO (Central Drugs Standard Control Organization) is responsible for issuing the directive. * State/UT Drugs Controllers are responsible for ensuring compliance by manufacturers within their jurisdiction. * NCCPvPI (National Coordination Centre for Pharmacovigilance Programme of India) played a crucial role in signal detection and recommendation. * Subject Expert Committee (SEC) was involved in the deliberation and recommendation process. * **Timelines/Procedures:** While the document does not explicitly state a timeline, it requests that "Action taken in this regard may be intimated to this office." This implies that the CDSCO expects prompt action from the State/UT Drugs Controllers and the manufacturers. * **Specific Implementation:** The implementation centers on the manufacturers updating their package inserts, labels, and promotional literature regarding Cefepime to include urticaria as an adverse drug reaction. **8. Expected Outcomes / Impact of Changes:** The likely intended outcome *of these specific changes* introduced by the amendment is: * **Increased Awareness:** Improved awareness among healthcare professionals and patients about the potential for Urticaria as a side effect of Cefepime. * **Better Monitoring and Reporting:** A potential increase in the reporting of Urticaria cases associated with Cefepime, contributing to a more comprehensive understanding of its safety profile. * **Improved Patient Safety:** Ultimately, the aim is to improve patient safety by enabling more informed decision-making and potentially earlier detection and management of this adverse reaction. **9. Conclusion:** The CDSCO directive mandating the inclusion of Urticaria as an adverse drug reaction in Cefepime labeling represents a significant step towards enhanced patient safety. The amendment, driven by pharmacovigilance data, requires manufacturers to update their product information, ensuring that healthcare professionals and patients are adequately informed about this potential risk. This change emphasizes the importance of ongoing drug safety monitoring and the responsiveness of regulatory bodies to emerging safety signals.

Key Entities Referenced